Efficacy of the MydCombi on Pupillary Dilation in Pediatric and Adult Patients

To raise the standard of care, improve the overall patient experience and streamline practice flow, Eyenovia has developed an innovative mydriatic to be delivered as a microdose by a specialized dispenser. While still achieving effective pupil dilation, MydCombi has the potential to increase patient throughput at practicing offices by decreasing time spent eye dropping patients, eliminating time wasted waiting between drop instillations and ensuring more accurate drug delivery. The proposed study hopes to demonstrate the non-inferiority of using MydCombi to achieve pupillary dilation in patients compared to standard of care eye drops.

NCT Number	NCT06366217
Lead Sponsor	University of California, San Francisco
Conditions	Dilation, Pupil Reaction Absent
Enrollment	100 participants
Start Date	2024-09-30
Primary Completion	2024-12-31 (estimated)
Study Completion	2024-12-31 (estimated)
Updated on ClinicalTrials.gov	2024-09-19